HVAX
Investment Objective
HVAX seeks to replicate, to the extent possible and net of expenses, the performance of an index that is designed to provide exposure to the performance of global, publicly listed companies generally engaged in the development and production of vaccines, therapeutics and diagnostics. Currently, HVAX seeks to replicate, directly or indirectly, the performance of the Solactive Global Vaccines and Infectious Diseases Index, net of expenses. HVAX seeks to hedge any U.S. dollar portfolio exposure back to the Canadian dollar at all times.
Fund Details
The NAV chart above only shows the historical daily net asset value per unit (NAV) of the ETF, and identifies the various distributions made by the ETF, if any. The distributions are not treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses. The chart is not a performance chart and is not indicative of future NAV values which will vary.
The Growth of 10K chart above is based on the historical daily net asset value per unit (NAV) of the ETF, and represents the value of an initial investment into the ETF of $10,000 since its inception, on a total return basis. Distributions, if any, are treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses where paid by the fund. The chart is not a performance chart and is not indicative of future value which will vary.
Annualized Performance (%) *
1mo | 3mo | 6mo | YTD | 1 yr | 3 yr | 5 yr | 10 yr | SIR** | |
---|---|---|---|---|---|---|---|---|---|
Horizons Global Vaccines and Infectious Diseases Index ETF | 1.21 | -10.55 | -9.40 | -8.36 | -14.69 | -- | -- | -- | -28.39 | Solactive Global Vaccines and Infectious Diseases Index | 1.45 | -10.64 | -8.50 | -7.79 | -14.58 | -- | -- | -- | -28.86 |
**Fund performance since inception on October 26, 2021, as at April 30, 2023
Calendar Year Performance (%) *
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|---|---|---|
Horizons Global Vaccines and Infectious Diseases Index ETF |
-- | -- | -- | -- | -- | -- | -- | -32.13 | Solactive Global Vaccines and Infectious Diseases Index | -- | -- | -- | -- | -- | -- | -- | -32.74 |
Distributions
Year | Ex-Dividend Date | Record Date | Payment Date | Payment Amount | Reinvested Non-Cash Distributions | Distribution Period |
---|---|---|---|---|---|---|
2022 | 12/29/2022 | 12/30/2022 | 01/12/2023 | 0.10324 | — | Annual |
Sector Allocation
As at April 28, 2023Health Care | 100.00% |
Geographic Exposure
As at April 28, 2023United States | 64.36% |
France | 10.31% |
China | 9.50% |
Germany | 8.18% |
Britain | 4.36% |
Denmark | 1.92% |
South Korea | 1.37% |
Top 10 Holdings
As at May 29, 2023Security Name | Weight |
---|---|
CureVac NV | 6.27% |
Moderna Inc | 5.44% |
Pfizer Inc | 5.21% |
BioNTech SE - ADR | 5.13% |
Vaxcyte Inc | 5.04% |
Sanofi SA - ADR | 4.99% |
Vir Biotechnology Inc | 4.74% |
Maravai LifeSciences Holdings Inc Cl A | 4.64% |
Merck & Co Inc | 4.56% |
3SBio Inc | 4.16% |
Holdings are subject to change. Download full prior business day: Holdings
Education
Regulatory and Legal
Investment Objective
HVAX seeks to replicate, to the extent possible and net of expenses, the performance of an index that is designed to provide exposure to the performance of global, publicly listed companies generally engaged in the development and production of vaccines, therapeutics and diagnostics. Currently, HVAX seeks to replicate, directly or indirectly, the performance of the Solactive Global Vaccines and Infectious Diseases Index, net of expenses. HVAX seeks to hedge any U.S. dollar portfolio exposure back to the Canadian dollar at all times.
Fund Details
The NAV chart above only shows the historical daily net asset value per unit (NAV) of the ETF, and identifies the various distributions made by the ETF, if any. The distributions are not treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses. The chart is not a performance chart and is not indicative of future NAV values which will vary.
The Growth of 10K chart above is based on the historical daily net asset value per unit (NAV) of the ETF, and represents the value of an initial investment into the ETF of $10,000 since its inception, on a total return basis. Distributions, if any, are treated as reinvested, and it does not take into account sales, redemption, distribution or optional charges or income taxes payable by any security holder. The NAV values do contemplate management fees and other fund expenses where paid by the fund. The chart is not a performance chart and is not indicative of future value which will vary.
Annualized Performance (%) *
1mo | 3mo | 6mo | YTD | 1 yr | 3 yr | 5 yr | 10 yr | SIR** | |
---|---|---|---|---|---|---|---|---|---|
Horizons Global Vaccines and Infectious Diseases Index ETF | 1.21 | -10.55 | -9.40 | -8.36 | -14.69 | -- | -- | -- | -28.39 | Solactive Global Vaccines and Infectious Diseases Index | 1.45 | -10.64 | -8.50 | -7.79 | -14.58 | -- | -- | -- | -28.86 |
**Fund performance since inception on October 26, 2021, as at April 30, 2023
Calendar Year Performance (%)
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|---|---|---|---|
Horizons Global Vaccines and Infectious Diseases Index ETF | -- | -- | -- | -- | -- | -- | -- | -32.13 | Solactive Global Vaccines and Infectious Diseases Index | -- | -- | -- | -- | -- | -- | -- | -32.74 |
Distributions
Year | Ex-Dividend Date | Record Date | Payment Date | Payment Amount | Reinvested Non-Cash Distributions | Distribution Period |
---|---|---|---|---|---|---|
2022 | 12/29/2022 | 12/30/2022 | 01/12/2023 | 0.10324 | Annual |
Sector Allocation
As at April 28, 2023Health Care | 100.00% |
Geographic Exposure
As at April 28, 2023United States | 64.36% |
France | 10.31% |
China | 9.50% |
Germany | 8.18% |
Britain | 4.36% |
Denmark | 1.92% |
South Korea | 1.37% |
Top 10 Holdings
As at May 29, 2023Security Name | Weight |
---|---|
CureVac NV | 6.27% |
Moderna Inc | 5.44% |
Pfizer Inc | 5.21% |
BioNTech SE - ADR | 5.13% |
Vaxcyte Inc | 5.04% |
Sanofi SA - ADR | 4.99% |
Vir Biotechnology Inc | 4.74% |
Maravai LifeSciences Holdings Inc Cl A | 4.64% |
Merck & Co Inc | 4.56% |
3SBio Inc | 4.16% |
Holdings are subject to change. Download full prior business day: Holdings